Lindsay Rosenwald | Dr Lindsay Rosenwald Biosciences Investment Company
RSS | Comments RSS
Lindsay Rosenwald Info | Tags: , ,

Dr. Lindsay A. Rosenwald: Lifetime Achievements

Comments (0)
September 16, 2011 at 10:15 am

Dr. Lindsay A. Rosenwald operates as a founder and chairman of the group of companies known as Paramount Capital group. These companies specialize in investment banking, venture capital, asset management, and direct investing within the biotechnology and life-sciences industry.

As a Wall Street biotechnology entrepreneur, Dr. Rosenwald is also a member of the Orion Biomedical Fund, LP and Orion Biomedical Offshore Fund, LP. These investment companies  both participate in financing start-up pharmaceutical research labs. Dr. Lindsay Rosenwald and his team seek out cutting edge bio-pharma companies and provide the needed capital for their research to move forward and he is responsible for the founding and re-capitalization of dozens of public and private companies.

Dr. Lindsay Rosenwald and the Paramount Capital portfolio of companies have found success with three new chemical entities recently approved by the Food and Drug Administration (FDA). They currently have dozens of other compounds in the clinical trial stage. One of the portfolio companies, PolaRx BioPharmaceuticals, Inc., has recently received final marketing approval for its leukemia drug called arsenic trioxide. The approval came quickly, only 30 months after the initial patient was treated in a corporate clinical trial.

One of his more successful acquisitions, Cougar Biotechnology, developed an exciting drug for late stage prostate cancer called abiraterone acetate. Dr. Lindsay Rosenwald has financed or founded a long list of other cutting edge companies such as Genta, Inc, Repligen Corporation, Cypress Bioscience, Inc., Discovery Laboratories, Inc., and Avigen, Inc.

Dr. Rosenwald graduated from Pennsylvania State University majoring in Finance and Economy graduating Beta Gamma Sigma in 1977. From 1977 to 1979, Dr. Rosenwald worked as an independent management consultant for several health care businesses. Later, he entered Temple University School of Medicine and graduated in 1983. Next Dr. Rosenwald took an internship at Abington Medical Hospital, working in a private medical practice until 1986. At this time, he took a position on Wall Street serving as a financial analyst specializing in medical research investment opportunities.

Today, Dr. Lindsay Rosenwald is well known in both the world of investing and the medical research field. He is a visionary with an eye toward innovation in drug research and development. He has over 20 years of experience in these areas and focuses on creating and promoting pioneering medical technologies that will enhance and transform the horizons of today’s life sciences and biotechnology companies.

Lindsay Rosenwald Info | Tags: ,

Opus Point Partners: Preparing for growth in the Life Science and Healthcare fields

Comments (0)
September 9, 2011 at 1:45 pm

OpusPoint Partners has been teaming up with individuals, investors, corporations and researchers with a unified mission to help fledgling companies achieve their goals, by providing the world with innovative solutions that will improve both the diagnosis and treatment of diseases. This investment into research companies that need the extra cash injection can only bode well for a world awaiting the progress made by these struggling companies to reap the benefits of great medical breakthroughs.

Mr. Michael S. Weiss in conjunction with Dr. Lindsay Rosenwald founded the OpusPoint Partners in 2009 and has steadfastly reaped success after success performing above the goals which would have been predicted. In less than two years, they’ve helped in the financing of over twenty companies, applying basic principles to best practices and processes. This has produced excellent rewards in both worlds of drug researching and business financing.

OpusPoint Partners has a promising future under the guidance of these two men who are both passionate about the world of biotechnology and have jointly founded other biotech companies through the years. With a combined 40 year track record between them in the fields of biotech and life sciences investing, there is no doubt that their experience and expertise would be instrumental in changing the way that the diagnosis and subsequent medical treatment of patients is handled.

Biotech investing is expected to be taken to a new level and OpusPoint Partners and Dr. Lindsay Rosenwald have raised the standards for advising and investing in biotechnical facilities by insisting on a strong set of values which are then reinforced by strong business principles. Investors are then provided with optimal returns with minimized risk, a formula which has already been proven effective by their successes.

Overcoming age-old techniques and procedures in medicine and healthcare will require additional effort but Dr. Rosenwald believes that this can be achieved while remaining within ethical boundaries as long as there is an injection of time, money and dedication.

The temptation to ignore ethics in exchange for greater profits has to be resisted if the founding principle of OpusPoint Partners is to be maintained. This principle is built on strong business connections with both the biotechnology and investment communities, thereby establishing a strong and successful conglomeration of partners that remain committed to honesty and integrity within the world of life science and healthcare.

The key to continued achievements in this area is the practice of integrity which has been stamped by honest investing and full open disclosure. True strength comes when companies and industry leaders have established strong relationships sharing the same values that understand that integrity is an inbuilt part of every organization’s culture and not just a good business practice. The world has become more competitive and business leaders are facing temptations of using less than ethical tactics in order to provide positive outcomes from their clinical trials to force an improvement in their earnings and profits.

OpusPoint Partners has proven that it is firmly committed to its shareholders made up of investors and employees and being different by remaining fair in all of its dealings especially when it comes to the investigating, testing and manufacture of drugs.

Dr. Lindsay Rosenwald is no stranger to merging biotechnology with financial investing. On July 10, 2009, Johnson and Johnson acquired a company called Cougar Biotech Labs for approximately one billion dollars which Dr. Rosenwald had founded under the name Cougar Biotechnology Inc. This Los Angeles based company performs research on experimental cancer drugs and has captured the interest of researchers and investors with some impressive experimental drugs that show promise. The company has already achieved success with one of these drugs which has shown great results in the treatment of latter staged prostate cancer.

Dr. Rosenwald has more than 17 years of experience as a biotechnology entrepreneur on Wall Street he has actively founded and recapitalized both private and public companies that are focused on biotechnology and life sciences. His B. S. in Finance from Pennsylvania State University and M. D. from the Temple University School of Medicine was very useful in his management of the Aries Funds (1994 to 2000) and the Orion Fund (2002-2006). The Aries fund has applied more than $1 Billion on healthcare investments while the Orion Fund has dedicated itself to private biotechnology investing in projects like PIPEs.

Dr. Lindsay Rosenwald has formed close connections to the biotechnology-finance industry leaders and is currently a member of the Board of Directors at the Republican Jewish coalition. OpusPoint Partners has geared up to prepare for the advances in healthcare and life science. Additional time and money will be invested in order to be the leaders in the latest innovations that are expected to revolutionize how healthcare is delivered. Their vision is to see a world improved by their collective input into healthcare and medicine, knowing that the future of mankind is stronger and healthier.

LindsayRosenwald | Tags: , ,

Lindsay Rosenwald One Step Ahead In Field Of LifeScience & HealthCare Investment

Comments (0)
June 8, 2011 at 1:56 pm

OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.

At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

Older Posts »
Powered by WordPress | j2-simple v1.0.1 | Utah Web Design | Utah SEO | Log in

Optimized by SEO Ultimate